TransMedics Group, Inc. filings document a Nasdaq-listed medical technology company built around the Organ Care System, National OCS Program and related transplant logistics services for lung, heart and liver transplantation. Its 8-K reports furnish operating results, guidance, tax valuation allowance disclosures and business drivers such as OCS case utilization, logistics revenue and aircraft assets.
Other filings cover material agreements, including headquarters facilities and completed aircraft acquisitions, as well as executive transitions, compensatory arrangements, inducement awards and proxy-governance matters. The company's disclosures also describe its common stock listing, board and shareholder voting matters, executive compensation, clinical program updates and FDA-related device disclosures.
TransMedics Group, Inc. (TMDX) director David Weill purchased 1,336 shares of common stock in an open-market or private transaction on September 11, 2026 at $81.63 per share. Following this transaction, he directly holds 16,392 shares of TransMedics common stock. No Rule 10b5-1 trading plan is reported for this purchase.
TransMedics Group, Inc. (TMDX) announced a leadership transition in its finance organization and reiterated its financial outlook. The Board appointed Fernando Araujo as Chief Financial Officer and Treasurer effective September 21, 2026, succeeding Gerardo Hernandez, who will move into advisory and commercial roles through April 2027.
The company reaffirmed its full-year 2026 revenue guidance of $737 million to $757 million, representing approximately 22% to 25% year-over-year growth, excluding any revenue from its investment in PAD Aviation Service GmbH. Araujo’s compensation includes a $590,000 base salary, performance-based bonus eligibility, a $200,000 sign-on bonus, and equity awards, with defined severance and change-in-control protections.
TransMedics Group, Inc. director James R. Tobin reported a bona fide gift transfer of 18,000 shares of common stock on 2026-08-17 from an indirect holding titled "The Tobin 2024 Family Trust," leaving that trust with 0 shares. Following this reporting, Tobin holds 6,981 shares of TransMedics common stock directly and 155,146 shares indirectly through the "James R. Tobin 2012 Trust."
TransMedics Group reported financial results for the quarter ended June 30, 2026. Total revenue was $189.9 million, a 21% increase from $157.4 million in the prior-year quarter, driven by higher utilization of the Organ Care System in liver and heart through the National OCS Program and growth in logistics services. Product revenue was $111.2 million and service revenue was $78.8 million. Net income was $14.7 million, or $0.41 per diluted share, compared with $34.9 million, or $0.92 per diluted share, a year earlier. Adjusted net income was $16.2 million, or $0.44 per diluted share.
Gross margin was 60% versus 61% a year ago. Operating expenses rose to $89.5 million from $60.0 million, reflecting investment in OCS Kidney, next-generation OCS 3.0, clinical programs and infrastructure. Income from operations declined to $23.7 million, for a 12.5% operating margin, compared with $36.6 million and a 23.2% margin in the prior-year quarter. Cash totaled $472.7 million as of June 30, 2026. Management raised the low end of full-year 2026 revenue guidance to a range of $737 million to $757 million, representing approximately 22% to 25% growth versus the prior year and excluding revenue from the strategic investment in PAD Aviation completed on July 1, 2026.
TransMedics Group, Inc. officer Nicholas Corcoran reported equity compensation awards. He received 11,727 restricted stock units (RSUs), each representing a contingent right to one share of common stock, bringing his direct common stock holdings to 41,558 shares.
He was also granted a stock option for 17,784 shares of common stock at an exercise price of $71.23 per share, expiring on July 10, 2036. The option vests at 2.0833% per month starting after April 10, 2026 and is scheduled to be fully vested by April 10, 2030, subject to continued service.
Hernandez Gerardo reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. Chief Financial Officer Gerardo Hernandez received equity awards on 2026-07-10 consisting of 17,246 RSUs, each representing one share of common stock, and stock options for 26,153 shares at $71.23 per share, vesting monthly from April 10, 2026 through April 10, 2030. Following these grants, he holds 31,935 common shares directly and 26,153 options expiring July 10, 2036.
Hassanein Waleed H reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group President & CEO Waleed H. Hassanein received equity awards on July 10, 2026, including 49,669 restricted stock units and stock options for 112,984 shares at $71.23 per share, vesting monthly from April 2026 to April 2030.
Following these awards, he holds 171,093 shares directly and options on 112,984 shares, plus indirect holdings of 150,000 shares through the Hassanein 2026 Qualified Annuity Trust and 345,009 shares through the Waleed H. Hassanein Revocable Trust; a 150,000‑share transfer between these trusts was a change in the form of beneficial ownership exempt under Rule 16a-13.
TransMedics Group director Thomas J. Gunderson exercised stock options to acquire 19,285 shares of common stock at an exercise price of $2.21 per share on June 15, 2026. On the same date he sold 9,624 shares at $75.06 per share, and after these transactions he directly holds 16,642 common shares. A contextual note states that shares sold were used to cover the option exercise price and related tax withholding obligations.